Get started
Ocugen, Inc.Ocugen, Inc.Ocugen, Inc.

Ocugen, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

OCGN trade ideas

OCGN back to basicsOCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to the results. For now, speculation is probably playing a bigger role as we don't know much more beyond what Ocugen announced this week. Regardless, looking at chart levels, a quick Fib retracement shows a few "pain points" on the chart, namely the 618 fib that has been a frequent resistance level over the last few months. "On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN™; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%. “With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN™ has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN™.” - Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen. " Quote Source: 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
NASDAQ:OCGN
by PennyStocks101
$OCGN is gonna fall todayPupm&Dump trading strategy idea. $OCGN is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $8,48; stop-loss — $9,07; take-profit — $7,32. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:OCGNShort
by KozakHlib
OCGN "variant stew"Alot going on in this chart but bear(or bull) with me.. 100MA being tested, broke above trend line and alot of confluence occuring all at once while the "Variant" is the big talk of the days. Quite a bit of upside here if good PR comes out on OCGN. Otherwise we could see this get swatted right back down under the trend line and below the 100MA. My calls are in for a solid risk reward play here. Trade safe and have fun! SMASH that like button and let me know your thoughts in the comments!
NASDAQ:OCGNLong
by Verum0